BNP Paribas Knock-Out GNMSF/ DE000PD5YQQ8 /
2024-05-30 4:21:15 PM | Chg.+0.090 | Bid4:53:49 PM | Ask4:53:49 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.710EUR | +1.95% | - Bid Size: - |
- Ask Size: - |
Genmab A/S | 1,606.6292 - | 2078-12-31 | Call |
GlobeNewswire
04-30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
04-03
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
2023-10-17
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
2023-09-25
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
2023-09-04
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
2021-10-19
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
2021-09-20
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
2021-07-21
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021